EA201791110A1 - Сублингвальное введение рилузола - Google Patents

Сублингвальное введение рилузола

Info

Publication number
EA201791110A1
EA201791110A1 EA201791110A EA201791110A EA201791110A1 EA 201791110 A1 EA201791110 A1 EA 201791110A1 EA 201791110 A EA201791110 A EA 201791110A EA 201791110 A EA201791110 A EA 201791110A EA 201791110 A1 EA201791110 A1 EA 201791110A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sublingual
rhynesol
riluzole
disclosed
introduction
Prior art date
Application number
EA201791110A
Other languages
English (en)
Inventor
Владимир Корик
Роберт М. Берман
Original Assignee
Биохэвен Фармасьютикэл Холдинг Компани Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биохэвен Фармасьютикэл Холдинг Компани Лтд. filed Critical Биохэвен Фармасьютикэл Холдинг Компани Лтд.
Publication of EA201791110A1 publication Critical patent/EA201791110A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Раскрыто сублингвальное введение рилузола. В частности, настоящее изобретение относится к способу лечения психоневрологического расстройства или симптома с помощью введения сублингвального состава рилузола. Кроме того, раскрыт способ облегчения или уменьшения боли в ротовой полости с помощью сублингвального состава рилузола.
EA201791110A 2014-11-21 2015-11-17 Сублингвальное введение рилузола EA201791110A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462083068P 2014-11-21 2014-11-21
PCT/US2015/061106 WO2016081466A1 (en) 2014-11-21 2015-11-17 Sublingual administration of riluzole

Publications (1)

Publication Number Publication Date
EA201791110A1 true EA201791110A1 (ru) 2017-11-30

Family

ID=55077617

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791110A EA201791110A1 (ru) 2014-11-21 2015-11-17 Сублингвальное введение рилузола

Country Status (14)

Country Link
US (1) US20180153862A1 (ru)
EP (1) EP3220890A1 (ru)
JP (1) JP2017535612A (ru)
KR (1) KR20170137030A (ru)
CN (1) CN107735077A (ru)
AU (1) AU2015350142A1 (ru)
BR (1) BR112017010440A2 (ru)
CA (1) CA2967659A1 (ru)
EA (1) EA201791110A1 (ru)
IL (1) IL252283A0 (ru)
MX (1) MX2017006454A (ru)
PH (1) PH12017500933A1 (ru)
SG (1) SG11201703897SA (ru)
WO (1) WO2016081466A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN110305095A (zh) 2013-10-22 2019-10-08 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
EA038518B1 (ru) 2014-11-21 2021-09-09 Биохэйвен Фармасьютикал Холдинг Компани Лтд. Сублингвальный препарат рилузола
US9899038B2 (en) 2016-06-30 2018-02-20 Karen Elaine Khaleghi Electronic notebook system
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア
CN109963559A (zh) * 2016-09-15 2019-07-02 皮肤科技生命科学有限公司 舌下或颊部施用dim以治疗皮肤病
BR112020016256A2 (pt) * 2018-02-21 2020-12-15 AI Therapeutics, Inc. Terapia de combinação com apilimod e agentes gluta-matérgicos
US10235998B1 (en) 2018-02-28 2019-03-19 Karen Elaine Khaleghi Health monitoring system and appliance
WO2019199776A1 (en) * 2018-04-09 2019-10-17 The General Hospital Corporation Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
EP3801626A4 (en) * 2018-05-27 2022-02-23 Biohaven Pharmaceutical Holding Company Ltd. USE OF RILUZOL ORAL DISINFECTANT TABLETS TO TREAT DISEASES
AU2019322889A1 (en) * 2018-08-16 2021-03-04 Biohaven Therapeutics Ltd. Use of riluzole oral disintigrating tablets for treating diseases
US10559307B1 (en) 2019-02-13 2020-02-11 Karen Elaine Khaleghi Impaired operator detection and interlock apparatus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US5837287A (en) * 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
ES2235896T3 (es) * 1999-06-04 2005-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Uso de riluzol para el tratamaiento de la esclerosis multiple.
WO2003083067A2 (en) * 2002-03-28 2003-10-09 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
JP2011093849A (ja) * 2009-10-30 2011-05-12 Kissei Pharmaceutical Co Ltd トラニラストの易溶性粉末吸入製剤
US9241933B2 (en) * 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
EA201791043A1 (ru) * 2011-07-13 2017-09-29 Сайтокинетикс, Инк. Комбинированная терапия бокового амиотрофического склероза
IN2014DN07989A (ru) * 2012-03-01 2015-05-01 Pharnext

Also Published As

Publication number Publication date
EP3220890A1 (en) 2017-09-27
BR112017010440A2 (pt) 2017-12-26
CA2967659A1 (en) 2016-05-26
MX2017006454A (es) 2018-03-23
US20180153862A1 (en) 2018-06-07
WO2016081466A1 (en) 2016-05-26
KR20170137030A (ko) 2017-12-12
IL252283A0 (en) 2017-07-31
SG11201703897SA (en) 2017-06-29
JP2017535612A (ja) 2017-11-30
AU2015350142A1 (en) 2017-06-15
PH12017500933A1 (en) 2017-11-20
CN107735077A (zh) 2018-02-23

Similar Documents

Publication Publication Date Title
EA201791110A1 (ru) Сублингвальное введение рилузола
EA201790958A1 (ru) Сублингвальный препарат рилузола
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
MY197698A (en) Oxysterols and methods of use thereof
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
EA201790442A1 (ru) Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
NZ730092A (en) Use of cysteamine in treating infections caused by yeasts/moulds
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2017001103A (es) Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
MA40313A (fr) Composition pharmaceutique à base d'isotrétinoïne destinée à la voie orale
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
EA201491581A1 (ru) Везикулярные композиции
MX2016012758A (es) Composicion hiperosmolar de acido hialuronico.
MX2018011379A (es) Tratamiento del prurito uremico.
MX2016005645A (es) Composicion farmaceutica topica de acitretina.
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
RU2014154366A (ru) Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний
IN2013MU03428A (ru)
IN2014CH01391A (ru)
UA114811C2 (uk) Застосування акампросату та баклофену для лікування аміотрофічного бічного склерозу